Anti-tumour activity of aprotinin.
A malignant invasive fibrosarcoma in hamsters and a malignant mammary carcinoma in mice were each challenged with the broad spectrum proteinase inhibitor aprotinin (Trasylol). In both tumour systems, significant anti-tumour effects of aprotinin were observed. Variations in the site and dosage of aprotinin application were made in an attempt to improve the chemotherapeutic response.
D000230:Adenocarcinoma / Q000188:drug therapy / Q000473:pathology; D000818:Animals; D007611:Aprotinin / Q000008:administration & dosage / Q000627:therapeutic use*; D006224:Cricetinae; D005354:Fibrosarcoma / Q000188:drug therapy* / Q000473:pathology; D006801:Humans; D007279:Injections, Subcutaneous; D008325:Mammary Neoplasms, Experimental / Q000188:drug therapy* / Q000473:pathology; D051379:Mice; D009336:Necrosis; D009374:Neoplasms, Experimental / Q000188:drug therapy
D007611:Aprotinin